Viewing Study NCT06832202

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:45 AM
Ignite Modification Date: 2026-06-15 @ 10:28 PM
Study NCT ID: NCT06832202
Status: RECRUITING
Last Update Posted: 2025-06-15
First Post: 2025-02-12
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
Sponsor: Shanghai Henlius Biotech
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HER2-low Hormone Receptor Positive Breast Cancer View
Keywords: